期刊
JOURNAL OF HEADACHE AND PAIN
卷 15, 期 -, 页码 -出版社
BMC
DOI: 10.1186/1129-2377-15-47
关键词
Chronic migraine; Refractory chronic migraine; Disease progression; rCM classification
资金
- Nevro Corporation
- St Jude Medical
- Allergan
- Pfizer
- ACRAF
- Berlin-Chemie
- Allergan, Merck
- ATI
- Bayer Schering Pharma
- Biogen Idec
The debate on the clinical definition of refractory Chronic Migraine (rCM) is still far to be concluded. The importance to create a clinical framing of these rCM patients resides in the complete disability they show, in the high risk of serious adverse events from acute and preventative drugs and in the uncontrolled application of therapeutic techniques not yet validated. The European Headache Federation Expert Group on rCM presents hereby the updated definition criteria for this harmful subset of headache disorders. This attempt wants to be the first impulse towards the correct identification of these patients, the correct application of innovative therapeutic techniques and lastly aim to be acknowledged as clinical entity in the next definitive version of the International Classification of Headache Disorders 3 (ICHD-3 beta).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据